Background. Non-guideline-endorsed posttreatment courses of antibiotics for post-Lyme disease syndrome (PLDS) have been linked to adverse patient outcomes, but these findings have yet to be validated in large systematic evaluations.
Lyme disease, a bacterial infection caused by the Borrelia burgdorferi sensu lato complex, is endemic to the northeastern United States. However, laboratory-confirmed cases have been reported in 48 states, and the geographic distribution of Lyme disease has expanded [1] . A total of 275 589 incident cases of confirmed or probable Lyme disease were reported to the Centers for Disease Control and Prevention (CDC) during 2008-2015, making it the most commonly reported vector-borne disease in the United States [1] . Additionally, in a single year (2008), >3.3 million Lyme disease tests were performed at an estimated cost of nearly $500 million [2] .
Infectious Diseases Society of America (IDSA) guideline recommendations published in 2006 [3] , as well as more recent clinical reviews [4, 5] , support a single 2-to 3-week course of oral or parenteral antibiotic therapy for Lyme disease, or a 4-week course for patients with rheumatologic complications. Although the majority of patients recover fully after this recommended treatment, an estimated 10%-20% of patients treated for Lyme disease report persistent symptoms of fatigue, musculoskeletal pain, and neurologic or cognitive disturbances, such as disrupted sleep and impairment of executive functions [6] . Post-Lyme disease syndrome (PLDS), often colloquially described as "chronic Lyme disease" (although the IDSA and other guidelines recommend against use of this term as it implies persistent infection [7] ), refers to the lingering presence of subjective symptoms, nonspecific to Lyme, for >6 months following antibiotic therapy with activity against B. burgdorferi.
Whether continuing antibiotic therapy beyond the recommended duration could ameliorate the symptoms of PLDS is controversial. Both the IDSA and the European Federation of the Neurological Societies assert that while some patients report postinfection sequelae, there is no rationale for the use of long-term antibiotic therapy for PLDS given the consistent lack of convincing biologic or clinical evidence for the existence of chronic B. burgdorferi infection after completion of recommended treatment regimens for Lyme disease [3, 8] . While proponents of the practice [9] cite small, uncontrolled studies that have associated improvements in some PLDS symptoms with prolonged antibiotic courses [10] [11] [12] [13] , double-blind, randomized, placebo-controlled trials have consistently shown little to no benefit of extended or repeated antibiotic treatment for PLDS, with up to a 7.3% incidence of life-threatening complications from intravenous (IV) therapy [14] [15] [16] [17] .
Recently, the CDC reported several additional confirmed episodes of significant patient harm resulting from months or even years of antibiotic therapy for PLDS, including case reports of septic shock, osteomyelitis, Clostridium difficile colitis, and paraspinal abscess [18] . All patients described in the CDC report received multiple oral and/or IV drugs for PLDS, including antibiotics, antiparasitics, and other nonstandard modalities [19] with no in vitro activity against B. burgdorferi. In its report, the CDC called for systematic investigations to assess the "scope and consequences of adverse effects resulting from treatment of persons with a diagnosis of chronic Lyme disease" [18] . The present study, a systematic assessment of adverse events (AEs) associated with receipt of treatment for PLDS (PLDS-Tx), was conducted to address that need using a large sample of commercially insured enrollees.
METHODS

Design and Data Source
The study was a retrospective cohort analysis of medical and pharmacy claims derived from the Truven Health Market Scan Commercial Claims and Encounters Database for calendar years 2013-2015. The database includes de-identified claims and eligibility information for up to 50 million enrollees each year, covered by commercial health plans and employers located throughout the United States. All diagnoses identified for the present study were based on any of the first 4 diagnosis fields on claims for all settings, plus principal diagnosis and diagnosis-related group codes on inpatient hospital claims (Supplementary Table 1) .
Sample Selection and Cohort Identification
Patients were identified for the sample using (1) International Classification of Diseases, Ninth Revision (ICD-9) codes (through 30 September 2015) and International Classification of Diseases, Tenth Revision (ICD-10) codes (1 October 2015 through 31 December 2015) on medical claims; (2) Healthcare Common Procedure Coding System (HCPCS) codes for IV medications on medical claims; and (3) generic product names for oral antibiotics, obtained by matching National Drug Code numbers on pharmacy claims to the Truven Red Book. The sample was designed a priori to represent patients who were initially treated for Lyme disease using a recommended antibiotic regimen; were diagnosed with PLDS ≥6 months after the initial diagnosis; and were, for the PLDS, either treated with IV antibiotics, with or without oral antibiotics (cohort 1), treated with oral antibiotics, without IV antibiotics (cohort 2), or not treated with antibiotics (cohort 3). Combinations of IV and oral treatments were included in cohort 1 to maximize power to detect IV-related adverse effects, especially in patients receiving multiple pharmacotherapies, a concern highlighted in the CDC report [18] .
Lyme disease was defined as an ICD-9 diagnosis of 088.81 or ICD-10 diagnosis of A69.2. Oral antibiotic treatments for the initial presentation of Lyme disease included amoxicillin, azithromycin, cefuroxime, clarithromycin, doxycycline, or erythromycin for ≥10 days, dispensed from 14 days prior through 14 days after the initial Lyme disease diagnosis date (Supplementary Table 2 ). The 14-day spans were used to account for empiric treatment and minor treatment delays. IV antibiotic treatments, measured in the same time period, included azithromycin, cefotaxime, ceftriaxone, cefuroxime, erythromycin, or penicillin G. IV forms of clarithromycin and doxycycline were not measured because no specific HCPCS codes are available for these medications.
Because no ICD codes specific to PLDS are available, this condition was defined as either of the following, based on medical claims dated ≥6 months after the first Lyme disease claim date: (1) ≥1 medical claim(s) with a diagnosis of "late effects of other infectious and parasitic diseases" (ICD-9 code 139 or ICD-10 code B94) or (2) ≥1 medical claim(s) with a Lyme disease diagnosis and patient has ≥0.5 Lyme disease medical claims/month of treatment, measured from initial to final Lyme disease diagnosis claim date. A sensitivity analysis was limited to patients with ≥0.5 Lyme disease medical claims/month from initial Lyme disease diagnosis date to PLDS diagnosis date, defined below.
Measurement Time Periods
Each patient's PLDS diagnosis date was defined as the chronologically first date after the 6-month marker that met either criterion (1) or criterion (2) . If both criteria were met, the PLDS diagnosis date was defined based on criterion (1). PLDS-Tx was measured from 14 days prior through 14 days after the PLDS diagnosis date. In addition to the antibiotics included in the a priori design, additional IV medications, nonstandard for Lyme disease treatment, were identified through exception testing (Supplementary Table 3 ), reflecting the broader list of medications used in real-world practice to treat PLDS [18] .
For patients who received PLDS-Tx (cohorts 1 and 2), the treatment index date was defined as the first PLDS-Tx claim date in the -14-day/+14-day time span. For those not treated with any study medication (cohort 3), the treatment index date was assigned by calculating a random number from 1 to 14 (days), then summing that number with the PLDS diagnosis date (eg, PLDS diagnosis date = 3 March, random number = 7, treatment index date = 10 March). All outcomes were reported for the 90-day periods prior to (pre) and on and after (post) the treatment index date.
Identification of PLDS-Tx-Naive Subsample Based on Index Date
To provide a more specific test of treatment-emergent effects of PLDS-Tx, a subsample analysis was limited to patients who received no IV or oral PLDS-Tx during the 90-day pretreatment period (ie, PLDS-Tx-naive). Because this subsample identification was based on the 90-day pretreatment period, PLDS-Txnaive patients were included in all 3 PLDS-Tx cohorts. For example, a patient whose PLDS diagnosis date was 31 March and received IV treatment beginning on 1 April (treatment index date), but had no IV or oral PLDS-Tx from 1 January through 31 March (90-day pretreatment period), was defined as a PLDS-Tx-naive patient in cohort 1.
Outcomes
AE measures were based on literature indicating AEs common in either antibiotic treatment, IV treatment, or both [16, 18, [20] [21] [22] [23] [24] [25] [26] [27] (Supplementary Table 1 ).
Statistical Measures
Analyses were performed using SPSS version 24.0 software (IBM SPSS, Armonk, New York), with a priori α (critical P) = .05. Five composite measures were calculated as ≥1: (1) AE; (2) all-cause inpatient stay; (3) inpatient stay with ≥1 AE; (4) all-cause emergency department (ED) visit; and (5) ED with ≥1 AE. For each composite measure and for all individual AEs occurring in ≥50 patients in the postindex period, pre-and postindex prevalence rates were calculated as total number of patients with ≥1 event, divided by total cohort size (n). For the same measures, incidence rates were calculated as the percentage of patients with 0 preindex events and ≥1 postindex event. Fisher exact test assessed between-cohort statistical significance on incident event rates. Fisher exact test was chosen because of small expected cell counts in cohort 1 (the IV treatment group). Number needed to harm figures were also calculated.
RESULTS
Of 123 687 unique patients with ≥1 claim for Lyme disease, 13 444 (10.9%) met initial criteria for PLDS; and 10 893 had a diagnosis of "late effects of other infectious and parasitic diseases" ≥6 months after the initial Lyme disease diagnosis date and/or ≥0.5 medical claims per month with a diagnosis of Lyme disease (Figure 1 ). The mean (median) number of Lyme disease medical claims per month was 3.3 (1.9). After imposing all inclusion criteria, 3127 patients remained. Of treated patients, 61% in cohort 1 and 62% in cohort 2 were treated for ≥60 days, and more than one-half (54% cohort 1, 56% cohort 2) for ≥90 days. Of patients in cohort 1, 99 were treated with Lymeactive IV antibiotics, and 51 with other IV therapies (other antibiotics n = 41; immunoglobulins n = 10), with 38.7% of 150 receiving concomitant oral antibiotics. For the sample overall, composite rates of AE incidence were 18.7% for cohort 1, 16.8% for cohort 2, and 13.4% for cohort 3 (P = .019; Table 1 ). Between-group differences were larger in the PLDS-Tx-naive subsample: incidence rates of 25.7% for cohort 1, 17.7% for cohort 2, and 13.9% for cohort 3 (P = .026). The 3 most common AEs among treated patients were infection (20.4%), gastrointestinal disturbances (6.2%), and electrolyte abnormalities (2.6%) ( Table 2) .
Significant between-group differences in AE incidence rates-comparing IV, oral, and no PLDS-Tx-were noted for electrolyte imbalance (incidence rates of 4.0%, 1.5%, and 0.7%, respectively; P = .001) and infection (14.0%, 12.7%, and 9.3%; P = .006) ( Table 1 and Figure 2 ). Similar changes in prevalence from the pre-to postindex periods were additionally observed (eg, the rate of infection increased by 22 
, these patterns were similar or magnified in the PLDS-Tx-naive subsample, with incidence rates of 11.4%, 1.4%, and 0.7%, respectively (P < .001), for electrolyte imbalance and 14.3%, 15.1%, and 9.8%, respectively (P = .006), for infection.
All-cause and AE-related hospital stays and ED visits occurred at a higher incidence rate among treated than nontreated patients, particularly when treatment was intravenous (all P < .01; Table 1 and Figure 2 ). Of IV-treated patients, 7.3% experienced an incident all-cause hospitalization and 11.3% an incident all-cause ED visit, compared with, respectively, 2.2% and 3.4% of those treated with oral antibiotics and 0.9% and 1.9% of nontreated patients. Results for the PLDS-Tx-naive group were similar, except that the between-group difference in incidence rates was not statistically significant for ED visits. Results of the sensitivity Data are presented as percentages unless otherwise indicated.
Abbreviations: AE, adverse event; ED, emergency department; IV, intravenous; PLDS, post-Lyme disease syndrome. a Pre-and postindex periods are, respectively, the 90-day periods before and after the start date of the indicated therapy or the randomly assigned treatment index date. All diagnoses shown in analyses, limited to the subsample of patients who met the more stringent criterion for monthly number of Lyme disease claims, were also similar (Supplementary Table 4 ). Number needed to harm values for each significant incidence rate change indicate that treating a relatively small number of patients (<30) with IV products for PLDS, instead of no IV products or oral antibiotics, would be expected to result in 1 additional AE (Table 3) .
DISCUSSION
This analysis of a large, commercially insured US sample documented several significant potential harms associated with treatments for PLDS, especially when administered intravenously. Results were consistent with those of previous randomized controlled trials of PLDS-Tx [14] [15] [16] [17] , but extended them to a larger sample, more diverse treatments found in real-world practice [18] , and an expanded list of measured event rates specific to expected adverse outcomes of PLDS-Tx [16, 18, [20] [21] [22] [23] [24] [25] [26] [27] .
Of particular concern, this study was the first to demonstrate increased rates of all-cause hospitalization and ED visits following receipt of pharmacotherapy for PLDS that included oral antibiotics, IV antibiotics, or IV immunomodulators. One potential driver of this increased healthcare utilization is the substantial increase in both prevalence and incidence of infection rates associated with PLDS-Tx, which included antibiotics in 99% of treated patients. Additionally, an increased incidence of electrolyte imbalance was associated with PLDS-Tx. Although antibiotic-associated diarrhea not caused by C. difficile, which occurs in up to 25% of antibiotic-treated patients [21] , would appear to be the most likely cause of electrolyte imbalance, between-group differences in incidence of gastrointestinal disturbance were not statistically significant in this study. A plausible alternative explanation for this finding is potassium wasting linked to oral or parenteral administration of β-lactams, which may act as nonabsorbable anions [25] . Per IDSA guideline recommendations regarding outpatient parenteral antibiotic therapy, weekly monitoring of potassium is recommended for IV administration of select β-lactams [28] , which may account for the higher reported electrolyte imbalance prevalence and incidence rates for IV compared with oral treatment. Distinguishing morbidity caused by antibiotic/IV treatment from that caused by the disease process, in this case PLDS, is challenging with retrospective analyses. We addressed this problem by including a comparison group of patients who met inclusion criteria for PLDS, but were not treated with oral antibiotics or IV pharmacotherapies. If the observed PLDS-Txassociated incident AEs were the result of progressing PLDS alone, similar increases in event rates would have been expected in all 3 cohorts. Instead, decreases were noted for nearly all measured events, including hospitalization and ED visits, in the comparison group. It is possible that these patients received alternative treatments, such as emotional support services and other symptom-directed supportive care measures [7] . Which specific treatments are helpful for patients with PLDS, and therefore can be used as substitutes for the pharmacotherapies that were associated with harm in the present study, should be a subject of future research.
To the best knowledge of the authors, this is the first study to identify increases in all-cause inpatient stay and ED visit linked to PLDS-Tx, perhaps because the monitoring of AEs related to PLDS antibiotic therapy has historically been challenging. Even identifying the affected population may be difficult, owing to the lack of specific diagnosis codes and vague or inconsistent definitions of the diagnosis, which has been applied to patients never receiving appropriate initial therapy [29] or, conversely, patients lacking any clinical or serologic evidence that they were ever infected with Lyme disease at all. In the largest randomized controlled trial to assess the impact of longer-term antibiotic therapy for PLDS [14] , >75% of screened patients failed to meet inclusion criteria, and previous investigators had experienced similar challenges with respect to patient recruitment [16, 17] . For this reason, randomized controlled trials of PLDS-Tx to date had relatively small sample sizes (<50-300 patients) that lacked power to detect the rare but serious adverse effects identified in case studies. However, case studies failed to establish the prevalence of these adverse effects. Thus, in light of our findings, additional large database studies are needed to provide more information about AEs related to PLDS-Tx.
Limitations of the present study should be noted. Foremost, as in any study based on administrative claims data, identification of patients and outcomes is dependent on diagnoses reported by treating physicians. No subjective measures of patients' symptomatology were obtained, and no specific diagnosis code for PLDS is available. For that reason, study findings cannot be used to assess the population prevalence of PLDS, or to represent outcomes of symptomatic patients who did not seek treatment or were diagnosed with another disorder (eg, myalgia). Instead, findings represent the outcomes of patients with a relatively consistent history of medical care for diagnosed Lyme disease. Additionally, it is not possible to determine with certainty from claims data the reasons that a physician prescribes pharmacotherapy. Some treated patients may have had a condition other than Lyme disease that resulted in antibiotic/IV treatment; however, given their history of Lyme disease-related medical care, the timing of treatment relative to PLDS diagnosis, and previous reports of long-duration pharmacotherapies in this patient population [18] , this possibility seems unlikely. Mitigating these potential limitations and consistent with best practices for retrospective analyses of administrative data [30, 31] , the quasi-experimental design included both pre-vs posttreatment calculations and a comparison group of patients not receiving PLDS-Tx [32] ; a sensitivity analysis of an alternative sampling criterion for PLDS was performed; reported outcomes included all-cause measures to reflect the possibility of unexpected outcomes; and specific measured events were consistent with expected effects of prolonged antibiotic exposure (ie, biologic plausibility).
Second, some cases of Lyme disease could have occurred prior to the start date of the database; therefore, the initial treatment date in the present study cannot be interpreted as representing the first (incident) Lyme diagnosis for every patient's lifetime. To maximize sample size, we required only 30 days of eligibility prior All-cause inpatient stay 11.4 1.9 0.8 9 91
All-cause ED visit for the PLDS treatment-naive group not shown because the between-group incidence rate was not statistically significant.
Abbreviations: AE, adverse event; ED, emergency department; IV, intravenous; NNH, number needed to harm; PLDS, post-Lyme disease syndrome.
to the initial Lyme disease claim. Third, despite the large sample size, the absolute number of patients treated with IV therapies was small. Although this limitation shows that, as expected, use of IV treatments for PLDS is atypical, it also reduced power to identify specific rare events. Fourth, the study represents only treatments with specific medications, covered by health insurance. Finally, this study utilized US patient data, and North American B. burgdorferi sensu lato strains differ from those found in Europe. However, as our study assessed adverse effects of therapies common to treatment of all B. burgdorferi strains, we would not anticipate significantly different results using a European database.
In conclusion, use of antibiotic or immunomodulatory pharmacotherapies for PLDS was associated with significant increases in the incidence of hospitalizations, ED visits, infections, and electrolyte imbalance within 90 days, particularly when administered intravenously.
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